To Investigate the Safety, Tolerability and Pharmacodynamics of GSK2890457 in Healthy Volunteers and Subjects With Type 2 Diabetes

Inclusion Criteria

• •Subject able to understand and voluntarily provide the consent to participate in the study
• •18 - 70 years of age, inclusive, at the time of signing the informed consent and Body Mass Index (BMI) between 18.0 and 35.0 Kilogram (kg) per m\^2, inclusive
• •Understands and is willing, able and likely to be compliant with taking study drug and comply with all study procedures and restrictions
• •Subject is willing to consume the foods that are part of the standardized breakfast, lunch, and dinner
• •In good general health with no clinically significant and relevant abnormalities of medical history or physical examination which includes adequate renal function, alanine transaminase (ALT), alkaline phosphatase and bilirubin \<=1.5x Upper Limit of Normal (ULN )
• •QTcF \< 450 millisecond (msec); or QTcF \< 480msec for subjects with right Bundle Branch Block
• •Females must be post-menopausal
• •Females on hormone replacement therapy (HRT) must discontinue HRT to allow confirmation of post-menopausal status prior to study enrollment
• •Females who are \> 3 months postpartum and who have undergone a surgical sterilization procedure are eligible to participate in consultation with the GSK Medical Monitor
• •Parts B and C (Type 2 Diabetic Subjects)
• •All the criteria mentioned in Part A except Body Mass Index (BMI) should be between 30.0 and 42.0 kg per m\^2
• •Diagnosis of T2D for at least 3 months, as defined by the American Diabetes Association
• •All T2D subjects must meet label recommendations for metformin
• •For Part B, subjects must be willing to discontinue metformin and replace it with daily liraglutide administered by subcutaneous injection and they must meet label recommendations
• •No personal history or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2